The essential substance of its claim is malevolence and dishonesty in the department's implementation of the new framework with potentially dire consequences for patients in the form of the removal of medicines from the PBS.
If patient access will be the victim, then this debate needs to be public
October 7, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 5 September
September 5, 2025 - - Podcast -
Novartis ANZ appoints Marco Muscardo as ad-interim Country PresidentÂ
September 4, 2025 - - Latest News -
Australian industry looks to the UK as likely lesson for US 'Most Favored Nation'
September 4, 2025 - - Latest News -
Every new working group and every consultation squeezes more life out of reform, like a lemon wrung to its rind
September 4, 2025 - - Latest News -
The latest HTA Review report is a Dickensian tribute to policymaking and reform
September 3, 2025 - - Latest News -
Stakeholders could be mistaken for thinking the process is the point
September 3, 2025 - - Latest News -
Regulate the regulators - Why NDIS audit fees are failing providers and participants
September 3, 2025 - - Latest News